People · Operator
Named in public records as an officer, director or promoter · active 2009–2014 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Microbion Corp | — | Pharmaceuticals | Series B | $45.7M | $329.0M | 2009 |
Frank Kerins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frank Kerins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Zafrira Avnur | 1 | 4 |
| Julia Levy | 1 | 3 |
| Jason Harmon | 1 | 2 |
| Rodger May | 1 | 1 |
| Brett Baker | 1 | 1 |
| Karim Lalji | 1 | 1 |
| Steven Schellong | 1 | 1 |
| Jared Carney | 1 | 1 |
| Robert Gillam | 1 | 1 |
| Jarret Sha | 1 | 1 |
| Kaley Wilson | 1 | 1 |
| Roger Kuypers | 1 | 1 |
| Donald Rix | 1 | 1 |
| Tom Farquhar | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.